Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thymoma × Nivolumab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 100 Carcinoma, Non-Small-Cell Lung 86 Carcinoma, Renal Cell 53 Neoplasm Metastasis 36 Carcinoma, Hepatocellular 32 Squamous Cell Carcinoma of Head and Neck 31 Colorectal Neoplasms 30 Lung Neoplasms 29 Neoplasms 24 Hodgkin Disease 23 Urinary Bladder Neoplasms 21 Pancreatic Neoplasms 21 Carcinoma, Transitional Cell 19 Breast Neoplasms 19 Brain Neoplasms 17 Stomach Neoplasms 16 Prostatic Neoplasms 16 Small Cell Lung Carcinoma 15 Sarcoma 15 Multiple Myeloma 14 Head and Neck Neoplasms 14 Esophageal Neoplasms 14 Glioblastoma 11 Rectal Neoplasms 10 Neuroendocrine Tumors 10 Lymphoma 10 Uterine Cervical Neoplasms 9 Recurrence 9 Ovarian Neoplasms 9 Nasopharyngeal Carcinoma 9

Interventions

Sunitinib 5 pembrolizumab 4 Paclitaxel 4 Carboplatin 4 Radiotherapy 3 Cyclophosphamide 3 Cisplatin 3 selinexor 2 lenvatinib 2 Taxes 2 Ramucirumab 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Methylprednisolone 2 Erlotinib Hydrochloride 2 Chemoradiotherapy 2 zimberelimab 1 saracatinib 1 regorafenib 1 epacadostat 1 envafolimab 1 belinostat 1 avelumab 1 atezolizumab 1 amrubicin 1 alovudine 1 TP protocol 1 Radiofrequency Ablation 1 Radiation Dose Hypofractionation 1 Prednisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03134118 2023-02-21

NIVOTHYM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡